Table 1.
Patient demographics
| Sex | Age | Laboratory measured calprotectin | IBD type | IBD medication | Multi-vitamin on medication list | |
|---|---|---|---|---|---|---|
| No disease-1 | M | 54 | <5 | NA | NA | yes |
| No disease-2 | M | 41 | 41 | NA | NA | yes |
| No disease-3 | F | 27 | 13 | NA | NA | no |
| No disease-4 | F | 30 | <5 | NA | NA | yes |
| No disease-5 | F | 42 | <5 | NA | NA | yes |
| No disease-6 | F | 37 | <5 | NA | NA | no |
| IBD in remission-1 | M | 67 | 43 | Ulcerative pancolitis | Mesalamine | no |
| IBD in remission-2 | F | 53 | 81 | Ileocolonic Crohn’s disease | Certolizumab | no |
| IBD in remission-3 | F | 46 | 63 | UC with left sided colitis | Vedolizumab | yes |
| IBD in remission-4 | M | 23 | 54 | Ileal Crohn’s disease | Ustekinumab | no |
| IBD in remission-5 | M | 48 | 11 | Unspecified UC | 6-MP, Mesalamine | no |
| Active IBD-1 | M | 33 | 1,200 | Ulcerative proctitis | Mesalamine | no |
| Active IBD-2 | F | 58 | 634 | UC with left sided colitis | Vedolizumab | no |
| Active IBD-3 | F | 52 | 325 | Ulcerative proctosigmoiditis | Mesalamine, Infliximab | no |
| Active IBD-4 | F | 44 | 858 | Ileocolonic CD | Ustekinumab | yes |
| Active IBD-5 | F | 48 | 2,390 | Crohn’s Colitis | Mesalamine | no |
| Active IBD-6 | F | 33 | 2,610 | Ulcerative pancolitis | Infliximab | yes |